A clinical study of allogeneic hematopoietic stem cell transplantation in 23 patients with early T-cell precursor acute lymphoblastic leukemia

Yuanxin Zhu,Mingqing Zhu,Haiping Dai,Sining Liu,Jia Yin,Zheng Li,Qingya Cui,Xiaming Zhu,Depei Wu,Xiaowen Tang

DOI: https://doi.org/10.3760/cma.j.issn.0253-2727.2019.12.010

2019-01-01

Abstract:Objective Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a recently recognized high-risk T lymphoblastic leukemia subgroup.The optimal therapeutic approaches to adult patients with ETP-ALL are poorly characterized.In this study,we explore the efficacy and outcome of allogeneic hematopoietic stem cell transplantation(allo-HSCT) for ETP-ALL.Methods The clinical data of 23 patients with ETP-ALL receiving allo-HSCT from 2010 to 2018 were retrospectively analyzed.Patients with ETP-ALL were diagnosed based on the characteristic immunophenotypes.Second-generation sequencing was done in all patients.As to the donors,12 patients had haploidentical donors (HaploHSCT),7 HLA-matched sibling donors (Sib-HSCT) and 4 HLA-matched unrelated donors (URD-HSCT).Before transplantation,19 patients achieved complete remission (CR) and 4 patients without.Results The main clinical features of ETP-ALL included high white blood cell counts in 5 patients,splenomegaly in 14,lymphadenopathy in 19,and thymus masses in 5.According to cytogenetic and molecular characteristics,11 patients had gene mutations related to myeloid tumors,and 7 with high risk Karyotype.After first induction regimen,14/23 patients achieved CR.5 patients reached CR after more than 2 cycles of chemotherapy,while another 4 patients did not reach CR.After allo-HSCT,22 patients were successfully implanted.The median time of granulocyte and platelet reconstitution was + 12 and + 19 days.One patient died of transplant-related infection at + 14 days.The estimated 18-month overall survival (OS) and relapse-free survival (RFS) rates were (55.0± 14.4)％ and (48.1 ± 14.7)％ respectively.Transplant-related mortality was 4.3 ％.The median OS in patients achieving CR before transplantation was 20 months,however,that in patients without CR was only 13 months.OS and RFS between haplo-HSCT and sib-HSCT were comparable (P=0.460 and 0.420 respectively).Conclusions Allo-HSCT is an effective therapy in some patients with ETP-ALL.Salvage HSCT cannot overcome the poor outcome.Haplo-HSCT and sib-HSCT in ETP-ALL patients have the similar clinical outcome.